<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03481998</url>
  </required_header>
  <id_info>
    <org_study_id>SHR6390-Ib/II-201</org_study_id>
    <nct_id>NCT03481998</nct_id>
  </id_info>
  <brief_title>A Study of SHR6390 + Letrozole for First-Line Treatment of Postmenopausal Women With HR+/HER2- Advanced Breast Cancer</brief_title>
  <official_title>Phase 1b/2, Open-label Study of the Safety, Efficacy and Pharmacokinetics of Letrozole Plus SHR6390 (Oral CDK4/6 Inhibitor) For the First-line Treatment of HR Positive, HER2 Negative Advanced Breast Cancer in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Study is aimed to evaluate the safety SHR6390 plus Letrozole and to assess the effect of
      the combination on Advanced Breast Cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With adverse events (AEs) and serious adverse events (SAEs) at Phase 1</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v4.03.
Up to 24 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of SHR6390</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of SHR6390</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time of SHR6390 to reach the maximum concentration (Tmax)</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-time (t1/2) of SHR6390</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>Up to approximately 24 months.</time_frame>
    <description>ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ยกร30% decrease in the sum of diameters of target lesions) per RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) per RECIST 1.1</measure>
    <time_frame>Up to approximately 24 months.</time_frame>
    <description>PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) per RECIST 1.1</measure>
    <time_frame>Up to approximately 24 months.</time_frame>
    <description>DCR is defined as the percentage of participants in the analysis population who have a CR, PR or SD per RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to approximately 24 months.</time_frame>
    <description>Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v4.03.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive SHR6390 (at protocol defined dose levels) in combination with letrozole 2.5 mg, orally once daily (continuously).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR6390 (TBD), in combination with letrozole 2.5 mg, orally once daily (continuously).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR6390 + Letrozole (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR6390 (RP2D, recommended Phase 2 dose), in combination with letrozole 2.5 mg, orally once daily (continuously).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR6390</intervention_name>
    <description>SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment</description>
    <arm_group_label>Cohort 1 (Part 1)</arm_group_label>
    <arm_group_label>Cohort 2 (Part 1)</arm_group_label>
    <arm_group_label>SHR6390 + Letrozole (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole, 2.5mg, orally once daily (continuously)</description>
    <arm_group_label>Cohort 1 (Part 1)</arm_group_label>
    <arm_group_label>Cohort 2 (Part 1)</arm_group_label>
    <arm_group_label>SHR6390 + Letrozole (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has the pathologically-confirmed diagnosis of locally recurrent or metastatic,
             hormone-receptor positive, HER2 negative Breast Cancer.

          -  Age: 18 - 75 years old, postmenopausal women.

          -  No prior systemic anti-cancer therapy for advanced HR+ disease.

          -  Eastern Cooperative Oncology Group [ECOG] 0-1

          -  Measurable disease as per Response Evaluation Criterion in Solid Tumors [RECIST] 1.1

          -  Adequate organ and marrow function

        Exclusion Criteria:

          -  Confirmed diagnosis of HER2 positive disease

          -  Patients who received Non-steroidal aromatase inhibitors (letrozole or anastrozole) as
             neo/adjuvant therapy for breast cancer are eligible. If the prior neo/adjuvant therapy
             included letrozole or anastrozole, the disease-free interval must be greater than 12
             months from the completion of treatment until study entry.

          -  Patients who received prior treatment with any CDK4/6 inhibitor.

          -  Clinically significant cardiovascular and cerebrovascular diseases, including but not
             limited to severe acute myocardial infarction within 6 months before enrollment,
             unstable or severe angina, Congestive heart failure (New York heart association (NYHA)
             class &gt; 2), or ventricular arrhythmia which need medical intervention.

          -  Has known active central nervous system metastases.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binhe Xu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gang Chen, MD</last_name>
    <phone>+86 (021)50118422</phone>
    <email>chen_gang@shhrp.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guorong Li, PhD</last_name>
    <email>liguorong@shhrp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ha'erbin Tumor Hospital</name>
      <address>
        <city>Ha'erbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingyuan Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xian Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pin Zhang, MD</last_name>
      <email>zhang_pin@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CDK4/6 inhibitor</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Postmenopausal women</keyword>
  <keyword>Hormone-receptor positive</keyword>
  <keyword>HER2 negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

